A detailed history of Wells Fargo & Company transactions in Merus N.V. stock. As of the latest transaction made, Wells Fargo & Company holds 250 shares of MRUS stock, worth $12,807. This represents 0.0% of its overall portfolio holdings.

Number of Shares
250
Previous 536 53.36%
Holding current value
$12,807
Previous $24,000 41.67%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$39.81 - $60.2 $11,385 - $17,217
-286 Reduced 53.36%
250 $14,000
Q1 2024

May 10, 2024

BUY
$28.03 - $51.82 $15,024 - $27,775
536 New
536 $24,000
Q4 2022

Feb 13, 2023

SELL
$12.8 - $23.66 $553,139 - $1.02 Million
-43,214 Reduced 99.31%
300 $4,000
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $202,970 - $315,018
10,889 Added 33.38%
43,514 $872,000
Q2 2022

Aug 12, 2022

BUY
$13.98 - $29.25 $451,903 - $945,506
32,325 Added 10775.0%
32,625 $739,000
Q3 2020

Nov 05, 2020

SELL
$10.57 - $16.0 $8,456 - $12,800
-800 Reduced 72.73%
300 $4,000
Q2 2020

Aug 13, 2020

BUY
$10.5 - $17.36 $8,400 - $13,888
800 Added 266.67%
1,100 $18,000
Q1 2020

May 14, 2020

BUY
$11.34 - $19.44 $3,402 - $5,832
300 New
300 $4,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.35B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.